Alprostadil: Prostaglandin E1 for Erectile Dysfunction and Peripheral Artery Disease
Alprostadil is a synthetic form of prostaglandin E1 (PGE1), a naturally occurring lipid mediator with potent vasodilatory and smooth muscle relaxant properties. It was first isolated from seminal vesicles and is now produced synthetically for clinical use. Alprostadil has a relatively short half-life and is rapidly metabolized in the lungs and liver, which limits its systemic exposure when administered locally and makes it well suited for targeted vascular therapy.
Clinically, alprostadil occupies an important niche across several distinct therapeutic areas. It is used as a second-line treatment for erectile dysfunction in men who do not respond to or cannot use oral phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil. It also has established roles in the management of peripheral artery disease and critical limb ischemia, and in neonatal medicine for maintaining patency of the ductus arteriosus in newborns with certain congenital heart defects pending surgical correction. The pharmacological versatility of alprostadil stems from its action on multiple prostaglandin receptor subtypes found across the vasculature, smooth muscle, and ductal tissue.
Mechanism of Action
Alprostadil exerts its effects primarily through binding to prostaglandin E receptors, particularly EP2 and EP3 subtypes, located on smooth muscle cells of blood vessel walls and other target tissues. Upon receptor activation, alprostadil stimulates adenylyl cyclase through G-protein coupling, leading to an increase in intracellular cyclic adenosine monophosphate (cAMP). Elevated cAMP activates protein kinase A, which phosphorylates myosin light chain kinase, reducing its activity and preventing smooth muscle contraction. The net result is smooth muscle relaxation and vasodilation. In penile tissue, this cascade leads to relaxation of the smooth muscle in the corpus cavernosum and associated arteries, increasing arterial blood inflow and reducing venous outflow, thereby producing an erection. In the peripheral vasculature, the same mechanism reduces vascular resistance and improves blood flow in ischemic limbs, benefiting patients with peripheral artery disease. In neonates, alprostadil maintains or reopens the ductus arteriosus by relaxing ductal smooth muscle, which is normally kept patent by endogenous prostaglandins that diminish after birth. Additionally, alprostadil inhibits platelet aggregation through cAMP-mediated mechanisms, contributing to its favorable effects on microcirculation and blood viscosity in peripheral artery disease.
Indications
Alprostadil has three major clinical indications. First, it is used for the treatment of erectile dysfunction (ED) in adult men when oral therapies have failed or are contraindicated. Two main local delivery methods are available: intracavernous injection (SKAT, self-injection therapy) and intraurethral application (MUSE, medicated urethral system for erection). Both achieve local delivery to penile erectile tissue. Second, alprostadil is used intravenously or intra-arterially for the treatment of peripheral artery disease (PAD) and critical limb ischemia, where improved perfusion can reduce rest pain, facilitate ulcer healing, and in some cases prevent amputation in patients who are not candidates for surgical revascularization. Third, in neonatal medicine, intravenous alprostadil is administered to maintain patency of the ductus arteriosus in newborns with ductus-dependent congenital heart lesions such as pulmonary atresia, severe pulmonary stenosis, transposition of the great arteries, and other conditions requiring ductal flow to sustain pulmonary or systemic circulation until corrective surgery can be performed.
Dosage and Administration
For erectile dysfunction via intracavernous injection, the starting dose is typically 2.5 micrograms, administered by the patient himself after training by a healthcare professional. The dose is titrated upward based on response and tolerability, with most patients achieving a satisfactory erection with doses between 5 and 20 micrograms. The maximum recommended single dose is 40 micrograms, and injections should not be given more than once per 24-hour period or more than three times per week. For intraurethral application (MUSE), doses of 125 to 1000 micrograms are available. For peripheral artery disease, alprostadil is typically infused intravenously at 40 to 60 micrograms over 2 hours daily for several weeks, depending on clinical response. In neonates, continuous intravenous infusion begins at 0.05 to 0.1 micrograms per kilogram per minute and is titrated as needed to maintain ductal patency, with monitoring for systemic effects including apnea, which is common in very small neonates and may require ventilatory support.
Side Effects
The side effect profile of alprostadil varies by route of administration. With intracavernous injection, the most common adverse effect is pain at the injection site, which is reported by a substantial proportion of users and may affect adherence. Prolonged erection (priapism), defined as erection lasting more than four hours, represents the most serious complication and constitutes a urological emergency requiring immediate medical intervention to prevent permanent erectile tissue damage from ischemia. Fibrosis of the corpus cavernosum with repeated injections and penile curvature (Peyronie-like changes) can develop with long-term use. For intraurethral application, local urethral burning and minor urethral bleeding are the main concerns, as well as dizziness due to hypotension. For systemic intravenous infusions used in PAD, the main adverse effects are hypotension, flushing, headache, and diarrhea, reflecting systemic vasodilation. In neonates, the most clinically significant side effect is apnea, occurring in approximately 10 to 12 percent of cases, which necessitates careful monitoring and readiness for respiratory support. Other neonatal effects include fever, jitteriness, and cortical proliferation of long bones with prolonged high-dose use.
Interactions
Alprostadil may potentiate the hypotensive effects of antihypertensive agents, diuretics, and vasodilators when used systemically. Patients already receiving antihypertensive therapy for peripheral vascular disease require careful blood pressure monitoring during alprostadil infusions. In patients using anticoagulants such as heparin or warfarin, alprostadil's antiplatelet effects may enhance bleeding risk, and dose adjustment or additional monitoring may be required. Concurrent use of vasoactive agents in the neonatal setting requires careful hemodynamic monitoring. For intracavernous use, the combination with other vasoactive agents used in pharmacological erection induction (such as papaverine or phentolamine in combination preparations) increases the risk of prolonged erection and hypotension and must only be performed under specialized urological supervision. Alprostadil should not be combined with PDE5 inhibitors such as sildenafil, vardenafil, or tadalafil for erectile dysfunction, as this combination substantially increases the risk of severe hypotension and priapism.
Special Notes
Patients using intracavernous alprostadil for erectile dysfunction must be thoroughly trained in self-injection technique and must be clearly instructed about the emergency management of prolonged erection. Any erection lasting more than four hours must be treated immediately in an emergency department; failure to do so risks permanent erectile dysfunction due to ischemic damage to the corpus cavernosum. Contraindications for intracavernous use include a predisposition to priapism (e.g., sickle cell disease, multiple myeloma, leukemia), penile anatomical abnormalities, and known hypersensitivity to alprostadil. Alprostadil is not indicated for sexual stimulation in partners without erectile dysfunction. For peripheral artery disease treatment, patient selection and vascular assessment by a specialist are essential. In neonatal use, alprostadil infusion must be conducted in a neonatal intensive care setting with full monitoring capabilities and access to respiratory support.
Related Topics
Frequently Asked Questions
What is priapism and why is it a medical emergency?
Priapism is a prolonged, often painful erection lasting more than four hours that is not caused by sexual stimulation and does not resolve spontaneously. When caused by alprostadil, it results from excessive smooth muscle relaxation and increased blood inflow into the corpus cavernosum without adequate venous drainage. If left untreated, the sustained ischemia within the erectile tissue causes progressive hypoxia, acidosis, and ultimately irreversible fibrosis, leading to permanent erectile dysfunction. Emergency treatment typically involves aspiration of blood from the corpus cavernosum followed by injection of a sympathomimetic agent such as phenylephrine to induce detumescence. Time is critical: outcomes worsen significantly after six hours of ischemic priapism.
What is MUSE and how does it differ from intracavernous injection?
MUSE stands for Medicated Urethral System for Erection. It is a small pellet containing alprostadil that is inserted into the urethra using a disposable applicator. The alprostadil is absorbed through the urethral mucosa and diffuses into the corpus cavernosum and spongiosum, producing vasodilation and erection. MUSE is generally considered less effective than intracavernous injection, with lower rates of achieving a satisfactory erection. It is preferred by patients who are unwilling to self-inject, though urethral burning and discomfort are common. Unlike injection, it does not require needle use and has a lower risk of penile fibrosis. However, the risk of hypotension can affect the partner if vaginal absorption occurs during intercourse, so condom use may be recommended.
Why is alprostadil used in newborns with heart defects?
In certain congenital heart defects, the ductus arteriosus, a fetal blood vessel connecting the aorta and pulmonary artery, must remain open after birth to allow adequate blood flow to either the lungs or the body, depending on the specific anatomy. After birth, rising oxygen levels and falling prostaglandin levels normally trigger ductal closure. Alprostadil provides exogenous prostaglandin E1 to keep the ductus open, effectively buying time until surgical correction or palliation can be performed in a specialized cardiac center. Without this pharmacological support, some neonates with ductus-dependent lesions would deteriorate rapidly from hypoxemia or systemic hypoperfusion within hours to days of birth.
Sources
- EMA: Caverject (alprostadil) Summary of Product Characteristics, current version.
- Montague DK et al. AUA Guideline on the Pharmacologic Management of Premature Ejaculation. J Urol. 2010.
- Norgren L et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007.